Showing 1711 results
-
Press release /AutonoMe(TM) preloaded IOL delivery system provides easy, intuitive control for precise IOL insertion during cataract surgery New Clareon® IOL in vitro data and early clinical experience to…
-
Ad hoc release /Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth…
-
Press release /Uniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms60 projects in Phase 2 pipeline with 10+ advancing…
-
Press release /PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRNew simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from…
-
Press release /Priority Review based on data from the largest clinical trials conducted to date in each indication[1],[2] Designation will shorten FDA expected review time to within six months[3]; EMA also…
-
Ad hoc release /Alcon strategic review concludes that 100% spinoff in best interest of shareholders and consistent with the Novartis strategy of focusing as a medicines company Planned spinoff would create…
-
Press release /Paul Hudson wird zum CEO, Novartis Pharmaceuticals, und Bruno Strigini zum CEO, Novartis Oncology, ernannt; David Epstein wird Novartis verlassen Paul Hudson und Bruno Strigini werden in…
-
Ad hoc release /Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz: Key growth drivers include Entresto USD 569…